Pyrazolospiroketone derivatives for use as acetyl-COA carboxylase inhibitors
Patents Granted (Contd.) Α61Κ 31/438 (2006.01) (54) Title Pyrazolospiroketone derivatives for use as acetyl - COA carboxylase inhibitors (57) Abstract The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt thereof; wherein G is (II) or (III) R>, RJ and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal. (56) Documents Cited : SCOTT W. BAGLEY et at WO 2012/042433 Α1 FORM 25 (12) PATENT (19) ΑΡ (11) Patent No : ΑΡ 3499 (73) Appiicant(s) PFIZER INC., 235 East 42nd Street, New York, New York 10017, United (21) Application No: AP/P/2013/007129 States of America (22) Filing Date : 09.04.2012 (24) (45) (30) Priority Data (72) Inventors (33) Country (31) Number (32) Date SOUTHERS James Alfred Jr, United States of America US 61/478,240 22.04.2011 DOW Robert tee, United States of America GRIFFITH David Andrew, United States of America et al (84) Designated States; (74) Representative BW GH GM ΚΕ LR IS MW GALLOWAY & COMPANY, Zimbabwe ΜΖ ΝΑ RW SD SL SZ ΤΖ UG (51) International Classification : C07D 473/10(2006.01) Α61Ρ 3/10 (2006.01) C07D 519/00(2006.01) Α61Ρ 3/04 (2006.01) The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, diluent, or carrier. The compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in a method for treating a disease, condition or disorder that is modulated by the inhibition of acetyl-CoA carboxylase enzyme(s). The compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in a method as claimed in claim 3, wherein the disease, condition, or disorder is Type 2 diabetes, diabetes-related disorders, nonalcoholic fatty liver disease (NAFLD) or hepatic insulin resistance. The compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in a method as claimed in claim 3, wherein the disease, condition, or disorder is Type 2 diabetes.